• +1-646-491-9876
    • +91-20-67278686

    Search

    Non Alcoholic Fatty Liver Disease-Pipeline Review H2 2017

    Non Alcoholic Fatty Liver Disease-Pipeline Review H2 2017

    • Report Code ID: RW0001881455
    • Category Life Sciences
    • No. of Pages 202
    • Publication Month Jul-17
    • Publisher Name Global Markets Direct
    Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline Review H2 20

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline Review H2 2017 provides an overview of the Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline landscape.

    Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease. Nonalcoholic fatty liver disease is common and for most people causes no signs and symptoms and no complications. But in some people with nonalcoholic fatty liver disease the fat that accumulates can cause inflammation and scarring in the liver. The most common symptoms that bring NAFLD to medical attention are malaise fatigue and right upper quadrant or diffuse abdominal discomfort.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline Review H2 2017 provides comprehensive information on the therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) complete with analysis by stage of development drug target mechanism of action (MoA) route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics its complete research and development history and latest news and press releases.

    The Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes the molecules developed by Companies in Phase III Phase II Phase I Preclinical Discovery and Unknown stages are 2 15 11 22 5 and 1 respectively. Similarly the Universities portfolio in Preclinical stages comprises 2 molecules respectively.

    Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases company/university websites clinical trial registries conferences SEC filings investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) .
    - The pipeline guide reviews pipeline therapeutics for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise product description descriptive licensing and collaboration details R&D brief MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) therapeutics based on mechanism of action (MoA) drug target route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal)

    Reasons to buy

    - Procure strategically important competitor information analysis and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    Table of Contents 2
    List of Tables 5
    List of Figures 6
    Introduction 7
    Publisher Report Coverage 7
    Non Alcoholic Fatty Liver Disease (NAFLD)-Overview 8
    Non Alcoholic Fatty Liver Disease (NAFLD)-Therapeutics Development 9
    Pipeline Overview 9
    Pipeline by Companies 10
    Pipeline by Universities/Institutes 14
    Products under Development by Companies 15
    Products under Development by Universities/Institutes 18
    Non Alcoholic Fatty Liver Disease (NAFLD)-Therapeutics Assessment 19
    Assessment by Target 19
    Assessment by Mechanism of Action 23
    Assessment by Route of Administration 27
    Assessment by Molecule Type 29
    Non Alcoholic Fatty Liver Disease (NAFLD)-Companies Involved in Therapeutics Development 31
    Akcea Therapeutics Inc 31
    Allergan Plc 31
    Ardelyx Inc 32
    AstraZeneca Plc 32
    Betagenon AB 33
    Bird Rock Bio Inc 33
    Boehringer Ingelheim GmbH 34
    Can-Fite BioPharma Ltd 34
    Cerenis Therapeutics Holding SA 35
    CJ HealthCare Corp 35
    Conatus Pharmaceuticals Inc 36
    Corcept Therapeutics Inc 36
    CymaBay Therapeutics Inc 37
    Daewoong Pharmaceutical Co Ltd 37
    Dimerix Bioscience Pty Ltd 38
    Dr. Falk Pharma GmbH 38
    DURECT Corp 39
    Enanta Pharmaceuticals Inc 39
    Eternygen GmbH 40
    Galmed Pharmaceuticals Ltd 40
    Gemphire Therapeutics Inc 41
    Genfit SA 41
    Gilead Sciences Inc 42
    Huons Co Ltd 42
    Immuron Ltd 43
    Kyorin Pharmaceutical Co Ltd 43
    Matinas BioPharma Holdings Inc 44
    Metacrine Inc 44
    Miyarisan Pharmaceutical Company Ltd 45
    Nordic Bioscience A/S 45
    NovaTarg Therapeutics Inc 46
    Ocera Therapeutics Inc 46
    Pfizer Inc 47
    Renova Therapeutics Inc 47
    Sancilio & Company Inc 48
    Shenzhen HighTide Biopharmaceutical Ltd 48
    TaiwanJ Pharmaceuticals Co Ltd 49
    TCM Biotech International Corp 49
    Zydus Cadila Healthcare Ltd 50
    Non Alcoholic Fatty Liver Disease (NAFLD)-Drug Profiles 51
    (leucine + metformin hydrochloride + sildenafil citrate)-Drug Profile 51
    (leucine + PDE5 Inhibitor)-Drug Profile 53
    AC-261066-Drug Profile 54
    AF-102-Drug Profile 55
    AKCEA-ANGPTL3LRx-Drug Profile 56
    Aramchol-Drug Profile 58
    ARI-3037MO-Drug Profile 64
    AZD-4076-Drug Profile 66
    C-10-Drug Profile 68
    CBM-588-Drug Profile 70
    cenicriviroc mesylate-Drug Profile 72
    CER-209-Drug Profile 80
    CJ-14199-Drug Profile 82
    CORT-118335-Drug Profile 83
    dabigatran etexilate mesylate-Drug Profile 84
    DMX-300-Drug Profile 86
    Drug to Antagonize MCJ for Gastrointestinal Disorders-Drug Profile 87
    DUR-928-Drug Profile 88
    DWP-10292-Drug Profile 93
    EDP-305-Drug Profile 94
    elafibranor-Drug Profile 96
    emricasan-Drug Profile 105
    FGF-1 Program-Drug Profile 113
    FLB-12-Drug Profile 114
    gemcabene calcium-Drug Profile 115
    GS-9674-Drug Profile 120
    HTD-1801-Drug Profile 123
    HU-002-Drug Profile 124
    IMM-124E-Drug Profile 125
    KBP-089-Drug Profile 128
    KM-2702-Drug Profile 129
    liothyronine sodium-Drug Profile 130
    MAT-8800-Drug Profile 131
    MN-002-Drug Profile 132
    naltrexone hydrochloride-Drug Profile 134
    Namacizumab-Drug Profile 136
    namodenoson-Drug Profile 137
    ND-630-Drug Profile 143
    NLM-0100-Drug Profile 145
    norursodeoxycholic acid-Drug Profile 146
    O-304-Drug Profile 147
    oltipraz-Drug Profile 149
    ornithine phenylacetate-Drug Profile 150
    PF-06835919-Drug Profile 157
    RDX-023-Drug Profile 158
    RT-200-Drug Profile 159
    RT-210-Drug Profile 160
    saroglitazar-Drug Profile 161
    SC-410-Drug Profile 164
    seladelpar lysine-Drug Profile 165
    selonsertib-Drug Profile 169
    Small Molecule for Non-Alcoholic Steatohepatitis and Non-Alcoholic Fatty Liver Disease-Drug Profile 172
    Small Molecules for Non-Alcoholic Steatohepatitis and Non Alcoholic Fatty Liver Disease-Drug Profile 173
    Small Molecules to Activate AMPK for Fatty Liver Disease-Drug Profile 174
    Small Molecules to Inhibit NaCT for Metabolic Diseases-Drug Profile 175
    Synthetic Peptides for Non Alcoholic Fatty Liver Disease and Non Alcoholic Steatohepatitis-Drug Profile 176
    TCM-606F-Drug Profile 177
    tipelukast-Drug Profile 178
    Non Alcoholic Fatty Liver Disease (NAFLD)-Dormant Projects 183
    Non Alcoholic Fatty Liver Disease (NAFLD)-Discontinued Products 184
    Non Alcoholic Fatty Liver Disease (NAFLD)-Product Development Milestones 185
    Featured News & Press Releases 185
    Appendix 197
    Methodology 197
    Coverage 197
    Secondary Research 197
    Primary Research 197
    Expert Panel Validation 197
    Contact Us 197
    Disclaimer 198

    List of Tables

    Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD) H2 2017
    Number of Products under Development by Companies H2 2017
    Number of Products under Development by Companies H2 2017 (Contd..1) H2 2017
    Number of Products under Development by Companies H2 2017 (Contd..2) H2 2017
    Number of Products under Development by Universities/Institutes H2 2017
    Products under Development by Companies H2 2017
    Products under Development by Companies H2 2017 (Contd..1) H2 2017
    Products under Development by Companies H2 2017 (Contd..2) H2 2017
    Products under Development by Universities/Institutes H2 2017
    Number of Products by Stage and Target H2 2017
    Number of Products by Stage and Target H2 2017 (Contd..1) H2 2017
    Number of Products by Stage and Target H2 2017 (Contd..2) H2 2017
    Number of Products by Stage and Mechanism of Action H2 2017
    Number of Products by Stage and Mechanism of Action H2 2017 (Contd..1) H2 2017
    Number of Products by Stage and Mechanism of Action H2 2017 (Contd..2) H2 2017
    Number of Products by Stage and Route of Administration H2 2017
    Number of Products by Stage and Molecule Type H2 2017
    Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by Akcea Therapeutics Inc H2 2017
    Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by Allergan Plc H2 2017
    Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by Ardelyx Inc H2 2017
    Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by AstraZeneca Plc H2 2017
    Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by Betagenon AB H2 2017
    Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by Bird Rock Bio Inc H2 2017
    Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by Boehringer Ingelheim GmbH H2 2017
    Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by Can-Fite BioPharma Ltd H2 2017
    Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by Cerenis Therapeutics Holding SA H2 2017
    Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by CJ HealthCare Corp H2 2017
    Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by Conatus Pharmaceuticals Inc H2 2017
    Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by Corcept Therapeutics Inc H2 2017
    Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by CymaBay Therapeutics Inc H2 2017
    Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by Daewoong Pharmaceutical Co Ltd H2 2017
    Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by Dimerix Bioscience Pty Ltd H2 2017
    Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by Dr. Falk Pharma GmbH H2 2017
    Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by DURECT Corp H2 2017
    Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by Enanta Pharmaceuticals Inc H2 2017
    Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by Eternygen GmbH H2 2017
    Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by Galmed Pharmaceuticals Ltd H2 2017
    Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by Gemphire Therapeutics Inc H2 2017
    Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by Genfit SA H2 2017
    Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by Gilead Sciences Inc H2 2017
    Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by Huons Co Ltd H2 2017
    Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by Immuron Ltd H2 2017
    Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by Kyorin Pharmaceutical Co Ltd H2 2017
    Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by Matinas BioPharma Holdings Inc H2 2017
    Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by Metacrine Inc H2 2017
    Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by Miyarisan Pharmaceutical Company Ltd H2 2017
    Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by Nordic Bioscience A/S H2 2017
    Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by NovaTarg Therapeutics Inc H2 2017
    Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by Ocera Therapeutics Inc H2 2017
    Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by Pfizer Inc H2 2017
    Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by Renova Therapeutics Inc H2 2017
    Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by Sancilio & Company Inc H2 2017
    Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by Shenzhen HighTide Biopharmaceutical Ltd H2 2017
    Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by TaiwanJ Pharmaceuticals Co Ltd H2 2017
    Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by TCM Biotech International Corp H2 2017
    Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by Zydus Cadila Healthcare Ltd H2 2017
    Non Alcoholic Fatty Liver Disease (NAFLD)-Dormant Projects H2 2017
    Non Alcoholic Fatty Liver Disease (NAFLD)-Discontinued Products H2 2017

    List of Figures

    Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD) H2 2017
    Number of Products under Development by Companies H2 2017
    Number of Products by Top 10 Targets H2 2017
    Number of Products by Stage and Top 10 Targets H2 2017
    Number of Products by Top 10 Mechanism of Actions H2 2017
    Number of Products by Stage and Top 10 Mechanism of Actions H2 2017
    Number of Products by Routes of Administration H2 2017
    Number of Products by Stage and Routes of Administration H2 2017
    Number of Products by Top 10 Molecule Types H2 2017
    Number of Products by Stage and Top 10 Molecule Types H2 2017
    Akcea Therapeutics Inc
    Allergan Plc
    Ardelyx Inc
    AstraZeneca Plc
    Betagenon AB
    Bird Rock Bio Inc
    Boehringer Ingelheim GmbH
    Can-Fite BioPharma Ltd
    Cerenis Therapeutics Holding SA
    CJ HealthCare Corp
    Conatus Pharmaceuticals Inc
    Corcept Therapeutics Inc
    CymaBay Therapeutics Inc
    Daewoong Pharmaceutical Co Ltd
    Dimerix Bioscience Pty Ltd
    Dr. Falk Pharma GmbH
    DURECT Corp
    Enanta Pharmaceuticals Inc
    Eternygen GmbH
    Galmed Pharmaceuticals Ltd
    Gemphire Therapeutics Inc
    Genfit SA
    Gilead Sciences Inc
    Huons Co Ltd
    Immuron Ltd
    Kyorin Pharmaceutical Co Ltd
    Matinas BioPharma Holdings Inc
    Metacrine Inc
    Miyarisan Pharmaceutical Company Ltd
    Nordic Bioscience A/S
    NovaTarg Therapeutics Inc
    Ocera Therapeutics Inc
    Pfizer Inc
    Renova Therapeutics Inc
    Sancilio & Company Inc
    Shenzhen HighTide Biopharmaceutical Ltd
    TaiwanJ Pharmaceuticals Co Ltd
    TCM Biotech International Corp
    Zydus Cadila Healthcare Ltd

    Request for Sample

    Report Url http://www.reportsweb.com//non-alcoholic-fatty-liver-disease-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//non-alcoholic-fatty-liver-disease-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//non-alcoholic-fatty-liver-disease-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments